Parp mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson’s disease

Cell Death and Disease

Volumn 7, Issue 3, 2016, Pages

  Lehmann, S ^a   Costa, A C ^a   Celardo, I ^a   Loh, S H Y ^a   Martins, L M ^a  

^a MRC TOXICOLOGY UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARKIN; DROSOPHILA PROTEIN; NICOTINAMIDE; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE MUTATION; NERVE DEGENERATION; NONHUMAN; PARKIN MUTANT (DROSOPHILA); PARKINSON DISEASE; PRIORITY JOURNAL; ANIMAL; BRAIN; DIETARY SUPPLEMENT; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DROSOPHILA; DRUG EFFECTS; GENETICS; GENOTYPE; LONGEVITY; MALE; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MUTAGENESIS; PATHOLOGY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BRAIN; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; DROSOPHILA; DROSOPHILA PROTEINS; GENOTYPE; LONGEVITY; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MUTAGENESIS; NAD; NIACINAMIDE; PARKINSON DISEASE; POLY(ADP-RIBOSE) POLYMERASES; UBIQUITIN-PROTEIN LIGASES;

EID: 85016132680     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.72     Document Type: Article

References (41)

1. Celardo I, Martins LM, Gandhi S. Unravelling mitochondrial pathways to Parkinson's disease. Br J Pharmacol 2014; 171: 1943–1957.
2. Lehmann S, Martins LM. Insights into mitochondrial quality control pathways and Parkinson's disease. J Mol Med 2013; 91: 665–671.
3. Tufi R, Gandhi S, de Castro IP, Lehmann S, Angelova PR, Dinsdale D et al. Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease. Nat Cell Biol 2014; 16: 157–166.
4. Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 2003; 100: 4078–4083.
5. Park J, Lee SB, Lee S, Kim Y, Song S, Kim S et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006; 441: 1157–1161.
6. Whitworth AJ, Theodore DA, Greene JC, Benes H, Wes PD, Pallanck LJ. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc Natl Acad Sci USA 2005; 102: 8024–8029.
7. Canto C, Menzies KJ, Auwerx J. NAD(+) Metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab 2015; 22: 31–53.
8. Mouchiroud L, Houtkooper RH, Auwerx J. NAD(+) metabolism: a therapeutic target for age-related metabolic disease. Crit Rev Biochem Mol Biol 2013; 48: 397–408.
9. Sauve AA. NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther 2008; 324: 883–893.
10. Bai P, Canto C, Oudart H, Brunyanszki A, Cen Y, Thomas C et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab 2011; 13: 461–468.
11. Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 2012; 15: 838–847.
12. Cerutti R, Pirinen E, Lamperti C, Marchet S, Sauve AA, Li W et al. NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab 2014; 19: 1042–1049.
13. Felici R, Lapucci A, Cavone L, Pratesi S, Berlinguer-Palmini R, Chiarugi A. Pharmacological NAD-boosting strategies improve mitochondrial homeostasis in human complex I-mutant fibroblasts. Mol Pharmacol 2015; 87: 965–971.
14. Pirinen E, Canto C, Jo YS, Morato L, Zhang H, Menzies KJ et al. Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab 2014; 19: 1034–1041.
15. Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012; 13: 225–238.
16. Kim TW, Cho HM, Choi SY, Suguira Y, Hayasaka T, Setou M et al. (ADP-ribose) polymerase 1 and AMP-activated protein kinase mediate progressive dopaminergic neuronal degeneration in a mouse model of Parkinson's disease. Cell Death Dis 2013; 4: e919.
17. Wu XL, Wang P, Liu YH, Xue YX. Effects of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on blood-brain barrier and dopaminergic neurons of rats with lipopolysaccharide-induced Parkinson's disease. J Mol Neurosci 2014; 53: 1–9.
18. Yokoyama H, Kuroiwa H, Tsukada T, Uchida H, Kato H, Araki T. Poly(ADP-ribose) polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. J Neurosci Res 2010; 88: 1522–1536.
19. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994; 371: 346–347.
20. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993; 53: 3976–3985.
21. Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr 2008; 28: 115–130.
22. Alano CC, Garnier P, Ying W, Higashi Y, Kauppinen TM, Swanson RA. NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci 2010; 30: 2967–2978.
23. Alano CC, Ying W, Swanson RA. Poly(ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition. J Biol Chem 2004; 279: 18895–18902.
24. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002; 54: 375–429.
25. Ying W. NAD+ and NADH in cellular functions and cell death. Front Biosci 2006; 11: 3129–3148.
26. Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr 1998; 157(Suppl 2): S40–S44.
27. Ong CT, Van Bortle K, Ramos E, Corces VG. Poly(ADP-ribosyl)ation regulates insulator function and intrachromosomal interactions in Drosophila. Cell 2013; 155: 148–159.
28. Tulin A, Stewart D, Spradling AC. The Drosophila heterochromatic gene encoding poly(ADP-ribose) polymerase (PARP) is required to modulate chromatin structure during development. Genes Dev 2002; 16: 2108–2119.
29. Zhang P, Spradling AC. Insertional mutagenesis of Drosophila heterochromatin with single P elements. Proc Natl Acad Sci USA 1994; 91: 3539–3543.
30. Vos M, Esposito G, Edirisinghe JN, Vilain S, Haddad DM, Slabbaert JR et al. Vitamin K2 is a mitochondrial electron carrier that rescues pink1 deficiency. Science 2012; 336: 1306–1310.
31. Fall PA, Fredrikson M, Axelson O, Granerus AK. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov Disord 1999; 14: 28–37.
32. Hellenbrand W, Boeing H, Robra BP, Seidler A, Vieregge P, Nischan P et al. Diet and Parkinson's disease. II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 1996; 47: 644–650.
33. Bender DA, Earl CJ, Lees AJ. Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa. Clin Sci (Lond) 1979; 56: 89–93.
34. Wakade C, Chong R, Bradley E, Thomas B, Morgan J. Upregulation of GPR109A in Parkinson's disease. PLoS One 2014; 9: e109818.
35. Jia H, Li X, Gao H, Feng Z, Li X, Zhao L et al. High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease. J Neurosci Res 2008; 86: 2083–2090.
36. Anderson DW, Bradbury KA, Schneider JS. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism. Eur J Neurosci 2008; 28: 610–617.
37. Zuo L, Motherwell MS. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. Gene 2013; 532: 18–23.
38. Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Canto C et al. The NAD (+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 2013; 154: 430–441.
39. Costa AC, Loh SH, Martins LM. Drosophila Trap1 protects against mitochondrial dysfunction in a PINK1/parkin model of Parkinson's disease. Cell Death Dis 2013; 4: e467.
40. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440–9445.
41. Wexler EJ. Photoshop CS3 Extended for Biomedical Research [DVD-ROM and online course]. Lynda.com, Inc: Ventura, 2008.